Tuberculosis - Metabolism and respiration in the absence of growth

Nature Reviews Microbiology

Volumn 3, Issue 1, 2005, Pages 70-80

  Boshoff, Helena I M ^a   Barry III, Clifton E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE;

BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BACTERIUM CULTURE; COLONY FORMING UNIT; DISEASE COURSE; FATTY ACID OXIDATION; GENETIC TRANSCRIPTION; GLUCONEOGENESIS; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; LUNG TUBERCULOSIS; MICROENVIRONMENT; MOLECULAR MECHANICS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; THORAX RADIOGRAPHY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CITRIC ACID CYCLE; GLUCONEOGENESIS; HUMANS; MODELS, ANIMAL; MYCOBACTERIUM TUBERCULOSIS; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; RIBOFLAVIN; TUBERCULOSIS;

ANIMALIA; BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; PRIMATES;

EID: 11144250804     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1065     Document Type: Review

References (90)

1. Corbett, E. L. et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163, 1009-1021 (2003).
2. Jagirdar, J. & Zagzag, D. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 323-344 (Lippincott Williams & Wilkins, Philadelphia, 2004).
3. Bates, J. H. in The Mycobacteria: A Sourcebook (eds Kubica, G. P. & Wayne, L. G.) 991-1005 (Marcel Dekker, New York, 1984).
4. Daley, C. L. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 85-99 (Lippincott William & Wilkins, Philadelphia, 2004).
5. Condos, R. & Rom, W. N. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 285-299 (Lippincott Williams & Wilkins, Philadelphia, 2004).
6. Vandiviere, H. M., Loring, W. E., Melvin, I. & Willis, S. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am. J. Med. Sci. 232, 30-37 (1956).
7. Kennedy, H. E., Vandiviere, H. M., Melvin, I. G. & Willis, H. S. The treated pulmonary lesion and its tubercle bacillus. III. Drug susceptibility studies. Am. J. Med. Sci. 233, 676-684 (1957).
8. Kennedy, H. E., Vandiviere, H. M. & Willis, H. S. The effects of extended incubation on propagability of tubercle bacilli. Am. Rev. Tuberc. 77, 802-814 (1958).
9. Kaplan, G. et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 71, 7099-7108 (2003).
10. Dannenberg, A. M. Pathogenesis of pulmonary Mycobacterium bovis infection: basic principles established by the rabbit model. Tuberculosis (Edinb.) 81, 87-96 (2001).
11. Canetti, G. Present aspects of bacterial resistance in tuberculosis. Am. Rev. Respir. Dis. 92, 687-703 (1965).
12. Lillebaek, T. et al. Stability of DNA patterns and evidence of Mycobacterium tuberculosis reactivation occurring decades after the initial infection. J. Infect. Dis. 188, 1032-1039 (2003).
13. Garay S. M. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 345-394 (Lippincott Williams & Wilkins, Philadelphia, 2004).
14. Capuano S. V. et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun. 71, 5831-5844 (2003).
15. McMurray, D. N., Collins, F. W. Dannenberg, A. M. & Smith, D. W. Pathogenesis of experimental tuberculosis in animal models. Curr. Top. Microbiol. Immunol. 215, 157-179 (1996).
16. Chan, J., Tanaka, K., Carroll, D., Flynn, J. & Boom, B. R. Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63, 736-740 (1995).
17. MacMicking, J. D. et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl Acad. Sci. USA 94, 5243-5248 (1997).
18. Flynn, J. L., Scanga, C. A., Tanaka, K. E. & Chan, J. Effects of aminoguanidine on latent murine tuberculosis. J. Immunol. 160 1796-1803 (1998).
19. Scanga, C. A. et al. l] Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect. Immun. 67, 4531-4538 (1999).
20. McCune, R. M., McDermott, W. & Tompsett, R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104, 763-802 (1956).
21. McCune, R. M. & Tompsett, R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J. Exp. Med. 104, 737-762 (1956).
22. de Wit, D., Wootton, M., Dhillon, J. & Mitchison, D. A. The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tuber. Lung Dis. 76, 555-562 (1995).
23. Garnier, T. et al. The complete genome sequence of Mycobacterium bovis. Proc. Natl Acad. Sci. USA 100, 7877-7882 (2003).
24. Fuller, C. L., Flynn, J. L. & Reinhart, T. A. In situ study of abundant expression of proinflammatory chemokines and cytokines in pulmonary granulomas that develop in cynomolgus macaques experimentally infected with Mycobacterium tuberculosis. Infect. Immun. 71, 7023-7034 (2003).
25. Walsh, G. P. et al. The Philippine cynomolgus monkey (Macaca fasicularis) provides a new nonhuman primate model of tuberculosis that resembles human disease. Nature Med. 2, 430-436 (1996).
26. Langermans, J. A. et al. Divergent effect of bacillus Calmette-Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc. Natl Acad. Sci. USA 98, 11497-11502 (2001).
27. Wayne, L. G. & Hayes, L. G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64, 2062-2069 (1996).
28. Wayne, L. G. & Sohaskey C. D. Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139-163 (2001).
29. Wayne, L. G. & Hayes, L. G. Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis. Tuber. Lung Dis. 79, 127-132 (1998).
30. Muttucumaru, D. G., Roberts, G., Hinds, J., Stabler, R. A. & Parist, T. Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis (Edinb) 84, 239-246 (2004).
31. Sohaskey, C. D. & Wayne, L. G. Role of narK2X and narGHJI in hypoxic upregulation of nitrate reduction by Mycobacterim tuberculosis. J. Bacteriol. 185, 7247-7256 (2003).
32. Boshoff, H. I. et al. The transcriptional responses of M. tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279, 40174-40184 (2004).
33. Sherman, D. R. et al. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin. Proc. Natl Acad. Sci. USA 98, 7534-7539 (2001).
34. Dawes, S. S. et al. Ribonucleotide reduction in Mycobacterium tuberculosis: function and expression of genes encoding class Ib and class II ribonucleotide reductases. Infect. Immun. 71, 6124-6131 (2003).
35. Durbach, S. I. et al. DNA alkylation damage as a sensor of nitrosative stress in Mycobacterium tuberculosis. Infect Immun. 71, 997-1000 (2003).
36. Boshoff, H. I., Reed, M. B., Barry, C. E., 3rd & Mizrahi, V. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 113, 183-193 (2003).
37. Tsolaki , A. G. et al. Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. Proc. Natl Acad. Sci. USA 101, 4865-4870 (2004).
38. Hirsh, A. E., Tsolaki, A. G., DeRiemer, K., Feldman, M. W. & Small, P. M. Stable association between strains of Mycobacterium tuberculosis and their human host populations. Proc. Natl Acad. Sci. USA 101, 4871-4876 (2004).
39. Daniel, J. et al. Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J. Bacteriol. 186, 5017-5030 (2004).
40. Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A. & Duncan, K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43, 717-731 (2002).
41. Dahl, J. L. et al. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc. Natl Acad. Sci. USA 100, 10026-10031 (2003).
42. Hampshire, T. et al. Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms? Tuberculosis (Edinb) 84, 228-238 (2004).
43. Voskuil, M. I., Visconti, K. C. & Schoolnik, G. K. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) 84, 218-227 (2004).
44. Kornberg, A., Rao, N. N. & Ault-Riche, D. Inorganic polyphosphate: a molecule of many functions. Annu. Rev. Biochem. 68, 89-125 (1999).
45. Hu, Y., Coates, A. R. & Mitchison, D. A. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47, 653-657 (2003).
46. Hu, Y. et al. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J. Bacteriol. 182, 6358-6365 (2000).
47. Mitchison, D. A. The search for new sterilizing antituberculosis drugs. Front. Biosci. 9, 1059-1072 (2004).
48. Hondalus, M. K. et al. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Immun. 68, 2888-2898 (2000).
49. Smith, D. A., Parish, T., Stoker, N. G. & Bancroft, G. J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect. Immun. 69 1142-1150 (2001).
50. Pavelka, M. S., Chen, B., Kelley, C. L., Collins, F. M. & Jacobs W. R. Vaccine efficacy of a lysine auxotroph of Mycobacterium tuberculosis. Infect. Immun. 71, 4190-4192 (2003).
51. Jackson, M. et al. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. 67, 2867-2873 (1999).
52. Sambandamurthy, V. K. et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nature Med. 8, 1171-1174 (2002).
53. De Voss, J. J. et al. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential A growth in macrophages. Proc. Natl Acad. Sci. USA 97, 1252-1257 (2000).
54. McKinney, J. D. et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406, 735-738 (2000).
55. Darwin, K. H., Ehrt, S., Gutierrez-Ramos, J. C., Weich, N. & Nathan, C. F. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 302, 1963-1966 (2003).
56. Voskuil, M. I. et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 198, 705-713 (2003).
57. Nathan, C. & Shiloh, M. U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl Acad. Sci. USA 97, 8841-8848 (2000).
58. Roberts, D. M., Liao, R. P., Wisedchaisri, G., Hol, W. G. & Sherman, D. R. Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis. J. Biol. Chem. 279, 23082-23087 (2004).
59. Schnappinger, D. et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J. Exp. Med. 198, 693-704 (2003).
60. Kana, B. D. et al. Characterization of the cydAB encoded cytochrome bd oxidase from Mycobacterium smegmatis. J. Bacteriol. 183, 7076-7086 (2001).
61. Poole, R. K. & Cook, G. M. Redundancy of aerobic respiratory chains in bacteria? Routes, reasons and regulation. Adv. Microb. Physiol. 43, 165-224 (2000).
62. Wayne, L. G. & Sramek, H. A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38, 2054-2058 (1994).
63. Brooks, J. V., Furney S. K. & Orme, I. M. Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43, 1285-1288 (1999).
64. Dhillon, J., Allen, B. W., Hu, Y. M., Coates, A. R. & Mitchison, D. A. Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis. 2, 736-742 (1998).
65. Desai, C. R. et al. Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. J. Assoc. Physicians India 37, 694-697 (1989 ).
66. Boon, C. & Dick, T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J. Bacteriol. 184, 6760-6767 (2002).
67. Parish, T. et al. Deletion of two-component regulatory systems increases the virulence of Mycobacterium tuberculosis. Infect. Immun. 71, 1134-1140 (2003).
68. Malhotra, V. et al. Disruption of response regulator gene, devR, leads to attenuation in virulence of Mycobacterium tuberculosis. FEMS Microbiol. Lett. 231, 237-245 (2004).
69. Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nature Rev. Cancer 4, 437-447 (2004).
70. Fenhalls, G. et al. In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. Infect. Immun. 70, 6330-6338 (2002).
71. Primm, T. P. et al. The stringent response of Mycobacterium tuberculosis is required for long-term survival. J. Bacteriol. 182, 4889-4898 (2000).
72. Lorenz, M. C. & Fink, G. R. Life and death in a macrophage: role of the glyoxylate cycle in virulence. Eukaryot. Cell 1 657-662 (2002).
73. Prigneau, O. et al. Genes involved in β-oxidation, energy metabolism and glyoxylate cycle are induced by Candida albicans during macrophage infection. Yeast 20, 723-730 (2003).
74. Timm, J. et al. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients. Proc. Natl Acad. Sci. USA 100, 14321-14326 (2003).
75. Fritz, C., Maass, S., Kreft, A. & Bange, F. C. Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific. Infect. Immun. 70, 286-291 (2002).
76. Weber, I., Fritz, C., Ruttkowski, S., Kraft, A. & Bange, F. C. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol. Microbiol. 35, 1017-1025 (2000).
77. Nakano, M. M. & Zuber, P. Anaerobic growth of a 'strict aerobe' (Bacillus subtilis). Annu. Rev. Microbiol. 52, 165-190 (1998).
78. Eschbach, M. et al. Long-term anaerobic survival of the opportunistic pathogen Pseudomonas aeruginosa via pyruvate fermentation. J. Bacteriol. 186, 4596-4604 (2004).
79. van Hellemond, J. J., van der Klei A, van Weelden, S. W. & Tielens, A. G. Biochemical and evolutionary aspects of anaerobically functioning mitochondria. Philos. Trans. R. Soc. Lond. B Biol. Sci. 358, 205-213.
80. Bacon, J. et al. The influence of reduced oxygen availability on pathogenicity and gene expression in Mycobacterium tuberculosis. Tuberculosis (Edinb) 84, 205-217 (2004).
81. Ragsdale, S. W. Pyruvate ferredoxin oxidoreductase and its radical intermediate. Chem. Rev. 103, 2333-4236 (2003).
82. King, G. M. Uptake of carbon monoxide and hydrogen at environmentally relevant concentrations by mycobacteria. Appl. Environ. Microbiol. 69, 7266-7272 (2003).
83. Nanba, H., Takaoka, Y. & Hasegawa, J. Purification and characterization of formate dehydrogenase from Ancylobacter aquaticus strain KNK607M, and cloning of the gene. Biosci. Biotechnol. Biochem. 67, 720-728 (2003).
84. Park, H. D. et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol. Microbiol. 48, 833-843 (2003).
85. 420-dependent glucose-6-phosphate dehydrogenase in Mycobacterium and Nocardia species, but absence from Streptomyces and Corynebacterium species and methanogenic Archaea. FEMS Microbiol. Lett. 146, 129-134 (1997).
86. Deppenmeier, U. The membrane-bound electron transport system of Methanosarcina species. J. Bioenerg. Biomembr. 36, 55-64 (2004).
87. 2-oxidizing subunit. Eur. J. Biochem. 267, 5810-5814 (2000).
88. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
89. Sassetti, C. M., Boyd, D. H. & Rubin, E. J. Genes required for mycobacterial growth defined by high-density mutagenesis. Mol. Microbiol. 48, 77-84 (2003).
90. Stover, C. K. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962-966 (2000).